Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator

Autophagy

Volumn 8, Issue 11, 2012, Pages 1657-1672

  Luciani, Alessandro ^a,b   Villella, Valeria Rachela ^a,c   Esposito, Speranza ^b,c   Gavina, Manuela ^a   Russo, Ilaria ^c   Silano, Marco ^d   Guido, Stefano ^c   Pettoello Mantovani, Massimo ^b   Carnuccio, Rosa ^c   Scholte, Bob ^e   De Matteis, Antonella ^f   Maiuri, Maria Chiara ^c,g   Raia, Valeria ^c   Luini, Alberto ^f,h   Kroemer, Guido ^g,i,j,k,l   Maiuri, Luigi ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^g INSERM   (France)

^h INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k CENTRE DE RECHERCHE DES CORDELIERS   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Autophagy; CFTR potentiators; Cystamine; Cystic fibrosis; Therapy

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; BECLIN 1; CYSTAMINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR POTENTIATOR; GENISTEIN; MANGANESE N,N' ETHYLENEBIS(3 METHOXYSALICYLIDENEAMINE); MEMBRANE AFFECTING AGENT; PHENYLALANINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VRX 532; VRX 770;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 84869389296     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.21483     Document Type: Article

References (55)

1. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010; 12:814-22; PMID:20811353; http://dx.doi.org/10.1038/ncb0910-814
2. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 2011; 27:107-32; PMID:21801009; http://dx.doi.org/10.1146/annurev-cellbio-092910-154005
3. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280-93; PMID:20965422; http://dx.doi.org/10.1016/j. molcel.2010.09.023
4. Codogno P, Mehrpour M, Proikas-Cezanne T. Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol 2012; 13:7-12; PMID:22166994
5. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469:323- 35; PMID:21248839; http://dx.doi.org/10.1038/nature09782
6. Sridhar S, Botbol Y, Macian F, Cuervo AM. Autophagy and disease: always two sides to a problem. J Pathol 2012; 226:255-73; PMID:21990109; http://dx.doi.org/10.1002/path.3025
7. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12:863-75; PMID:20711182; http://dx.doi.org/10.1038/ncb2090
8. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina DL, Settembre C, et al. Cystic fibrosis: a disorder with defective autophagy. Autophagy 2011; 7:104-6; PMID:21048426; http://dx.doi.org/10.4161/auto.7.1.13987
9. Abdulrahman BA, Khweek AA, Akhter A, Caution K, Kotrange S, Abdelaziz DH, et al. Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011; 7:1359- 70; PMID:21997369; http://dx.doi.org/10.4161/auto.7.11.17660
10. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet2009; 373:1891-904; PMID:19403164; http://dx.doi.org/10.1016/S0140-6736(09)60327-5
11. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. NEngl J Med 2005; 352:1992-2001; PMID:15888700;http://dx.doi.org/10.1056/NEJMra043184
12. Accurso FJ. Update in cystic fibrosis 2005. Am J RespirCrit Care Med 2006; 173:944-7; PMID:16632633;http://dx.doi.org/10.1164/rccm.2601006
13. Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, et al. Dynamic regulation of CFTR bicarbonate permeability by [Cl-]i and its role in pancreatic bicarbonate secretion. Gastroenterology 2010; 139:620-31; PMID:20398666; http://dx.doi.org/10.1053/j.gastro.2010.04.004
14. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999; 79(Suppl):S3-22; PMID:9922374
15. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:5121-88
16. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256:774-9; PMID:1375392; http://dx.doi.org/10.1126/ science.1375392
17. Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One 2009; 4:e4664; PMID:19247502; http://dx.doi.org/10.1371/journal.pone.0004664
18. Belcher CN, Vij N. Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies. Curr Mol Med 2010; 10:82-94; PMID:20205681; http://dx.doi.org/10.2174/156652410791065408
19. Anderson P. Emerging therapies in cystic fibrosis. Ther Adv Respir Dis 2010; 4:177-85; PMID:20530065; http://dx.doi.org/10.1177/1753465810371107
20. Ratjen F, Grasemann H. New therapies in cystic fibrosis. Curr Pharm Des 2012; 18:614-27; PMID:22229570; http://dx.doi.org/10.2174/138161212799315984
21. Mozzillo E, Franzese A, Valerio G, Sepe A, De Simone I, Mazzarella G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009; 10:162-7; PMID:19207231; http://dx.doi.org/10.1111/j. 1399-5448.2008.00451.x
22. Amaral MD. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies. Curr Drug Targets 2011; 12:683-93; PMID:21039334; http://dx.doi.org/10.2174/138945011795378586
23. Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 2011; 3:pii:a004499; PMID:21421917; http://dx.doi.org/10.1101/cshperspect.a004499
24. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, et al. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 2008; 180:7697-705; PMID:18490773
25. Luciani A, Villella VR, Vasaturo A, Giardino I, Raia V, Pettoello-Mantovani M, et al. SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 2009; 183:2775-84; PMID:19625650; http://dx.doi.org/10.4049/jimmunol.0900993
26. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra- Moran O, Galietta LJ, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115:2564-71; PMID:16127463; http://dx.doi.org/10.1172/JCI24898
27. Van Goor F Straley KS, Cao D, González J, Hadida S, Hazlewood A, et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. AJP - Lung Physiol 2006; 260: L1117-L1130; http://dx.doi.org/10.1152/ajplung.00169.2005
28. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010; 78:411-8; PMID:20501743; http://dx.doi.org/10.1124/mol.110.065862
29. Okiyoneda T, Barrière H, Bagdány M, Rabeh WM, Du K, Höhfeld J, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 2010; 329:805-10; PMID:20595578; http://dx.doi.org/10.1126/science.1191542
30. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med 2012; 18:81-91; PMID:22138491; http://dx.doi.org/10.1016/j.molmed.2011.10.003
31. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevúek P, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663-72; PMID:22047557; http://dx.doi.org/10.1056/NEJMoa1105185
32. Davis PB. Therapy for cystic fibrosis - the end of the beginning? N Engl J Med 2011; 365:1734-5; PMID:22047565; http://dx.doi.org/10.1056/NEJMe1110323
33. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67:12-8; PMID:21825083; http://dx.doi.org/10.1136/ thoraxjnl-2011-200393
34. Elborn JS. Fixing cystic fibrosis CFTR with correctors and potentiators. Off to a good start. Thorax 2012; 67:4-5; PMID:22058188; http://dx.doi.org/10. 1136/thoraxjnl-2011-201197
35. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137:1001- 4; PMID:19524504; http://dx.doi.org/10.1016/j. cell.2009.05.023
36. Gidalevitz T, Kikis EA, Morimoto RI. A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol 2010; 20:23-32; PMID:20053547; http://dx.doi.org/10.1016/j.sbi.2009.11.001
37. Okiyoneda T, Apaja PM, Lukacs GL. Protein quality control at the plasma membrane. Curr Opin Cell Biol 2011; 23:483-91; PMID:21571517; http://dx.doi.org/10.1016/j.ceb.2011.04.012
38. Jurkuvenaite A, Chen L, Bartoszewski R, Goldstein R, Bebok Z, Matalon S, et al. Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 2010; 42:363-72; PMID:19502384; http://dx.doi.org/10.1165/rcmb.2008-0434OC
39. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731:237-45; PMID:21516412; http://dx.doi.org/10. 1007/978-1-61779-080-5-20
40. Silvis MR, Bertrand CA, Ameen N, Golin-Bisello F, Butterworth MB, Frizzell RA, et al. Rab11b regulates the apical recycling of the cystic fibrosis transmembrane conductance regulator in polarized intestinal epithelial cells. Mol Biol Cell 2009; 20:2337-50; PMID:19244346; http://dx.doi.org/10.1091/mbc. E08-01-0084
41. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8:153-71; PMID:19153558; http://dx.doi.org/10.1038/nrd2780
42. Singh OV, Pollard HB, Zeitlin PL. Chemical rescue of deltaF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol Cell Proteomics 2008; 7:1099-110; PMID:18285607; http://dx.doi.org/10.1074/mcp. M700303-MCP200
43. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83:121-7; PMID:7553863; http://dx.doi.org/10.1016/0092-8674(95)90240-6
44. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358:761-4; PMID:1380673; http://dx.doi.org/10.1038/358761a0
45. Namkung W, Kim KH, Lee MG. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator. Gastroenterology 2005; 129:1979-90; PMID:16344066; http://dx.doi.org/10.1053/j. gastro.2005.08.049
46. Wilke M, Buijs-Offerman RM, Aarbiou J, Colledge WH, Sheppard DN, Touqui L, et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 2011; 10(Suppl 2):S152-71; PMID:21658634; http://dx.doi.org/10.1016/S1569-1993(11)60020-9
47. van Doorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, Bijman J, et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995; 14:4403-11; PMID:7556083
48. Legssyer R, Huaux F, Lebacq J, Delos M, Marbaix E, Lebecque P, et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res 2006; 7:134; PMID:17064416; http://dx.doi.org/10.1186/ 1465-9921-7-134
49. Raia V, Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Auricchio S, et al. Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax 2005; 60:773-80; PMID:15994249; http://dx.doi.org/10. 1136/thx.2005.042564
50. Amaral MD. Processing of CFTR: traversing the cellular maze - how much CFTR needs to go through to avoid cystic fibrosis? Pediatr Pulmonol 2005; 39:479- 91; PMID:15765539; http://dx.doi.org/10.1002/ppul.20168
51. Mosler K, Coraux C, Fragaki K, Zahm JM, Bajolet O, Bessaci-Kabouya K, et al. Feasibility of nasal epithelial brushing for the study of airway epithelial functions in CF infants. J Cyst Fibros 2008; 7:44- 53; PMID:17553758; http://dx.doi.org/10.1016/j.jcf.2007.04.005
52. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 2004; 164:923-33; PMID:15007060; http://dx.doi.org/10. 1083/jcb.200312018
53. Caohuy H, Jozwik C, Pollard HB. Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2 signaling pathway. J Biol Chem 2009; 284:25241-53; PMID:19617352; http://dx.doi.org/10.1074/jbc.M109.035345
54. Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M, Guido S, et al. Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010; 59:311-9; PMID:19951908; http://dx.doi.org/10.1136/gut.2009.183608
55. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del- CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108:18843-8; PMID:21976485; http://dx.doi.org/10.1073/pnas.1105787108